Organon, a healthcare company, completed the acquisition of Forendo Pharma, a drug development company, for $954m. “Despite the high prevalence of endometriosis, current treatment options are not adequately addressing the painful and challenging symptoms of women living with this disorder. Through our acquisition of Forendo, we hope to bring innovation to this therapeutic area and enable future treatment options – in line with our continued focus on building a robust pipeline that addresses a broad spectrum of conditions impacting women," Sandra Milligan, Organon Head of Research & Development.